Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Swiss Group for Clinical Cancer Research
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier:
NCT02051218
First received: January 29, 2014
Last updated: March 10, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2022
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)